Monday November 23 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Boehringer Ingelheim Pharma KG


Contact Details:
Birkendorferstr
Biberach
88397
Germany
Tel:++49 7351 54 7602
Fax:++49 7351 54 2187
Email:michael.mark@bc.boehringer-ingelheim.com
WWW:

www.boehringer-ingelheim.com/




Recent Publications by Boehringer Ingelheim Pharma KG:

The role of CGRP and nicotinic receptors in centrally evoked facial blood flow changes.
The release of CGRP in humans is associated with the occurrence of...
10th August, 2005
CNS Research, Boehringer Ingelheim Pharma KG, Birkendorfer Strasse 65, Neurosci Lett. 2005 Jun 10-17;381(1-2):120-4. Epub 2005 Feb 25.
DOI Direct Link
Influence of mechanical activation on the physical stability of salbutamol sulphate.
In order to obtain the optimal particle size distribution for...
18th August, 2004
Boehringer Ingelheim Pharma KG, Ingelheim am Rhein, Germany. Eur J Pharm Biopharm. 2003 Nov;56(3):393-400.
Accumulation of radiolabelled platelets and fibrin on the carotid artery of rabbits after angioplasty: effects of heparin and dipyridamole.
We investigated the dynamic accumulation of platelets and fibrin after...
13th August, 2004
Department of Drug Discovery Support, Boehringer Ingelheim Pharma KG, Thromb Haemost. 2003 Dec;90(6):1179-86.
DOI Direct Link
Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents.
Quinoxalinone derivatives as prototypes of dual thrombin and factor Xa...
28th February, 2004
Department of Chemical Research, Boehringer Ingelheim Pharma KG, Bioorg Med Chem Lett. 2003 Jul 21;13(14):2297-302.
Heterocyclic thrombin inhibitors. Part 1: design and synthesis of amidino-phenoxy quinoline derivatives.
Amidino-phenoxy quinoline derivatives represent a new class of potent...
28th February, 2004
Department of Chemical Research, Boehringer Ingelheim Pharma KG, Bioorg Med Chem Lett. 2003 Jul 21;13(14):2291-5.

View more Boehringer Ingelheim Pharma KG research publications.

Boehringer Ingelheim Pharma KG Patents:

US Patent No.Title
6680384 Process for preparing 4,6-diaminopyrimido[5,4-d]pyrimidines
6773895 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
6777423 Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
6790856 Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
6800623 Method of treating schizophrenia

View more Boehringer Ingelheim Pharma KG patents.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 29 individuals from Boehringer Ingelheim Pharma KG using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 524 times since April 2007, the link to the organisation's website has been followed 66 times

Recent Search Terms used to find this page: Pharmacological Research Building Boehringer Ingelheim Pharma KG | .

Search for more companies in Biberach

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Boehringer Ingelheim Pharma KG

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.